Endocrine Abstracts

Background: Growth hormone deficiency (GHD) is an increasingly recognized potential consequence following traumatic brain injury (TBI). Outside of a formal, blinded RCT to demonstrate treatment effects, long term adherence to hGH replacement in a full reimbursement setting may serve as a pragmatic indicator of patient-perceived therapy benefits. Our objective was to evaluate adherence to therapy at one year for patients with GHD secondary...

Background: Growth hormone deficiency (GHD) is an increasingly recognized potential consequence following traumatic brain injury (TBI). Outside of a formal, blinded RCT to demonstrate treatment effects, long term adherence to hGH replacement in a full reimbursement setting may serve as a pragmatic indicator of patient-perceived therapy benefits. Our objective was to evaluate adherence to therapy at one year for patients with GHD secondary...

Background: Endogenous Cushing’s syndrome is caused by chronically elevated glucocorticoid levels. The most common etiology is ACTH hypersecretion from a pituitary adenoma; other causes include hypersecretion of cortisol from an adrenal source or ectopic ACTH secretion. Following successful treatment, a period of adrenal insufficiency is expected due to chronic suppression of the HPA axis. Onset and exacerbation of steroid-responsive conditions have been reported followin...

Background: Dopamine agonists (DA) are included in the management algorithm of acromegaly. Studies on cabergoline monotherapy report IGF-1 normalisation in between 0% and 100% of the patients during treatment periods ranging between 2.6 and 24 months. However, in many of these studies, previous radiotherapy is a confounding factor. Furthermore, real world data applying the current disease control criteria (normal IGF-1 and GH<1 mg/l) are not available. The aim of this stud...

Background & Aims: Neuroendocrine tumours (NET) are a heterogenous group of neoplasms that secrete peptides and neuroamines. For potentially malignant gastroenteropancreatic (GEP) NET, surgical resection represents the only curative option. Ten-year imaging surveillance programs using cross sectional imaging are recommended due to long time-to-recurrence following resection. We performed a retrospective chart review to evaluate radiation exposure associated with surveillan...

Background: Cabergoline monotherapy or in combination with somatostatin analogue (SSA) has been reported in few studies with IGF-1-normalization-rates 0%-100%(monotherapy) and 42%-60%(combination therapy). However, in these studies, inclusion of irradiated patients is a potential confounder and currently proposed disease control criteria (normal IGF-1, GH<1 mg/l) have not been applied.Aim: Investigate the efficacy of cabergoline monotherapy or as add...

Introduction: The WHO classification distinguishes G3NET as a separate entity. Literature on G3NETs is limited to case-reports and small case-series. We aimed to characterise G3NETs from a large tertiary centre.Methods: Retrospective analysis from NET database: 2012–2019. All referrals are discussed at a specialist NET-MDT before entry into clinical pathway. Core NET-MDT consists of a radiologist, nuclear-medicine radiologist, histopathologist, spec...

Introduction: Cabergoline is one of the medical treatments in acromegaly; it can be used alone or in combination with other available agents.Aim: To review the efficacy of cabergoline in patients with acromegaly treated in our centre.Patients and methods: Patients with acromegaly on cabergoline were identified from our Pituitary Registry. Clinical/laboratory/imaging data were collected and analysed.Results: F...

Introduction: Silent somatotroph Pituitary Neuroendocrine Tumours (PitNETs) are extremely rare (2−3% of surgically treated pituitary tumours) and data on their natural history and outcomes are scarce.Aim: To review systematically the cases of these tumours presenting in our Centre.Patients and methods: Patients with this diagnosis were identified from our Pituitary Registry and clinical/laboratory/imaging data were collected ...

Background: Metastatic disease in the pituitary (PM) is uncommon and the published literature mainly involves case reports and small case series. We aimed to analyze presenting manifestations and outcomes of patients diagnosed with PM in our pituitary centre.Methods: Retrospective review of our Pituitary Registry to identify patients with PM from 2006 to present. Clinical, radiological, and pathological data were collected and analysed.<p class="abst...